Drug Trial Radar · NCT06094010
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,100
Planned (sponsor's estimate)
Start
Nov 22, 2023
Primary completion
May 11, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 weeks, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study consists of two parts: Part A Surveillance and Part B Transmission. The main purpose of Part A is to evaluate the prevalence of pre-dose and treatment-emergent amino acid substitutions in pediatric participants' \<12 years with influenza treated with baloxavir marboxil. Part B will include a subset of Part A participants who have household contacts (HHCs) recruited to the study. Part B will evaluate the incidence of onward influenza transmission from pediatric index participants (IPs) under 5 years of age and those aged 5 to under 12 years, treated with baloxavir marboxil, to their HHCs. Participants will no longer be enrolled to Part B Transmission as per protocol version 3.
Conditions
- Influenza
Interventions
Baloxavir MarboxilDrug
Baloxavir marboxil will be administered as an oral suspension per body weight (≥80 kilograms \[kg\]: 80 milligrams \[mg\]; ≥20 kg to \< 80 kg: 40 mg; \<20 kg: 2 milligrams per kilogram \[mg/kg\]).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Percentage of Participants With Resistance-associated Pre-treatment SubstitutionsTime frame: Day 1 (At Baseline)
- Part A: Percentage of Participants With Resistance-associated Treatment-emergent SubstitutionsTime frame: Days 4, 6 and 10
Locations
52 sites in 4 countries. Site status is shown where the registry gives one.
Central Alabama Research
Birmingham, Alabama · Recruiting
Harrisburg Family Medical Center
Harrisburg, Arkansas · Recruiting
Kendall South Medical Center Inc.
Miami, Florida · Recruiting
Avanza Medical Research Center
Pensacola, Florida · Withdrawn
Tekton Research - Chamblee Georgia
Chamblee, Georgia · Withdrawn
Tekton Research Lawrenceville
Lawrenceville, Georgia · Withdrawn
Velocity Clinical Research at Primary Pediatrics Macon
Macon, Georgia · Completed
Clinical Research Prime
Idaho Falls, Idaho · Recruiting
Mishawaka Osteopathic Clinic
Mishawaka, Indiana · Recruiting
Kentucky Pediatric Research Center
Bardstown, Kentucky · Recruiting
Velocity Clinical Research Lafayette
Lafayette, Louisiana · Recruiting
Velocity Clinical Research, Slidell
Slidell, Louisiana · Completed
Velocity Clinical Research, Grand Island
Grand Island, Nebraska · Completed
Machuca Family Medicine
Las Vegas, Nevada · Completed
Ohio Pediatric Research Association
Dayton, Ohio · Completed
Helios Clinical Research, Inc (former Ventavia Research Group)
Middleburg Heights, Ohio · Recruiting
Frontier Clinical Research
Smithfield, Pennsylvania · Recruiting
Coastal Pediatric Research
Charleston, South Carolina · Completed
Tekton Research - Beaumont
Beaumont, Texas · Completed
Oak Cliff Research Company, LLC
Dallas, Texas · Active not recruiting
Mercury Clinical Research
Houston, Texas · Completed
Pioneer Research Solutions
Houston, Texas · Recruiting
Oak Cliff Research Company, LLC
Richardson, Texas · Completed
Sun Research Institute
San Antonio, Texas · Withdrawn
Tekton Research
San Antonio, Texas · Completed
Siena Research Network
Sugar Land, Texas · Recruiting
Velocity Clinical Research, Salt Lake City
West Jordan, Utah · Withdrawn
Frontier Clinical Research, LLC
Kingwood, West Virginia · Active not recruiting
"Medical Center - Bileva" Ltd
Blagoevgrad, Bulgaria · Recruiting
Medical Centre "Asklepii", OOD
Dupnitsa, Bulgaria · Completed
MHAT " St. Ivan Rilski " Kozloduy
Kozloduy, Bulgaria · Completed
MHAT Stamen Iliev AD
Montana, Bulgaria · Active not recruiting
MHAT City Clinic - Saint George
Montana, Bulgaria · Completed
SHATPPD Dr. Dimitar Gramatikov, Ruse Ltd.
Rousse, Bulgaria · Completed
MHAT Sliven - Military Medial Academy
Sliven, Bulgaria · Completed
AGPSMP Pediatric diseases South park OOD
Sofia, Bulgaria · Recruiting
Medical Center Hera Sofia
Sofia, Bulgaria · Completed
IN VIVO Sp. z o.o.
Bydgoszcz, Poland · Recruiting
NZOZ Vitamed
Bydgoszcz, Poland · Recruiting
Centrum Medyczne Pratia Częstochowa
Częstochowa, Poland · Recruiting
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.